Automate Your Wheel Strategy on PEN
With Tiblio's Option Bot, you can configure your own wheel strategy including PEN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PEN
- Rev/Share 32.9639
- Book/Share 33.3192
- PB 7.5443
- Debt/Equity 0.1704
- CurrentRatio 6.7538
- ROIC 0.0886
- MktCap 9803203767.0
- FreeCF/Share 4.1618
- PFCF 60.6548
- PE 66.0918
- Debt/Assets 0.1317
- DivYield 0
- ROE 0.1241
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PEN | BofA Securities | -- | Buy | -- | $320 | March 14, 2025 |
| Initiation | PEN | UBS | -- | Buy | -- | $305 | Jan. 21, 2025 |
| Initiation | PEN | Oppenheimer | -- | Outperform | -- | $275 | Dec. 17, 2024 |
| Upgrade | PEN | Wells Fargo | Equal Weight | Overweight | $190 | $275 | Dec. 11, 2024 |
| Initiation | PEN | Stifel | -- | Buy | -- | $238 | Sept. 18, 2024 |
| Initiation | PEN | Leerink Partners | -- | Outperform | -- | $263 | Sept. 3, 2024 |
News
Should You Add Penumbra Stock to Your Portfolio Right Now?
PEN
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: February 12, 2025 by: Zacks Investment Research
Sentiment: Positive
PEN continues to attract investor interest with its strong portfolio expansion and global expansion efforts.
Read More
About Penumbra, Inc. (PEN)
- IPO Date 2015-09-18
- Website https://www.penumbrainc.com
- Industry Medical - Devices
- CEO Adam Elsesser
- Employees 4500
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.